The DOI matches its Crossref record; 245 of the 245 references it cites were found in a registry or an index.
Gene Delivery Using Herpes Simplex Virus Vectors
Abstract
Herpes simplex virus (HSV) is a neurotropic DNA virus with many favorable properties as a gene delivery vector. HSV is highly infectious, so HSV vectors are efficient vehicles for the delivery of exogenous genetic material to cells. Viral replication is readily disrupted by null mutations in immediate early genes that in vitro can be complemented in trans, enabling straightforward production of high-titre pure preparations of non-pathogenic vector. The genome is large (152 Kb) and many of the viral genes are dispensable for replication in vitro, allowing their replacement with large or multiple transgenes. Latent infection with wild-type virus results in episomal viral persistence in sensory neuronal nuclei for the duration of the host lifetime. Transduction with replication-defective vectors causes a latent-like infection in both neural and non-neural tissue; the vectors are non-pathogenic, unable to reactivate and persist long-term. The latency active promoter complex can be exploited in vector design to achieve long-term stable transgene expression in the nervous system. HSV vectors transduce a broad range of tissues because of the wide expression pattern of the cellular receptors recognized by the virus. Increasing understanding of the processes involved in cellular entry has allowed preliminary steps to be taken towards targeting the tropism of HSV vectors. Using replication-defective HSV vectors, highly encouraging results have emerged from recent pre-clinical studies on models of neurological disease, including glioma, peripheral neuropathy, chronic pain and neurodegeneration. Consequently, HSV vectors encoding appropriate transgenes to tackle these pathogenic processes are poised to enter clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, gene delivery and gene therapy applications use 3 types of HSV vectors.”
From Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges (2020) · cites this paper as [111]
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90504-6 · Cited by 2,411
Dystrophin expression in the mdx mouse restored by stem cell transplantation
Gussoni, E., Soneoka, Y., Strickland, C. D., Buzney, E. A., Khan, M. K., Flint, A., Kunkel, L. M., & Mulligan, R. C. (1999) · Nature · doi:10.1038/43919 · Cited by 1,800
The Complete DNA Sequence of the Long Unique Region in the Genome of Herpes Simplex Virus Type 1
McGeoch, D. J., Dalrymple, M. A., Davison, A. J., Dolan, A., Frame, M. C., McNab, D., Perry, L. J., Scott, J. E., & Taylor, P. (1988) · Journal of General Virology · doi:10.1099/0022-1317-69-7-1531 · Cited by 1,618
Honess, R. W., & Roizman, B. (1974) · Journal of Virology · doi:10.1128/jvi.14.1.8-19.1974 · Cited by 1,415
Whitley, R. J., Kimberlin, D. W., & Roizman, B. (1998) · Clinical Infectious Diseases · doi:10.1086/514600 · Cited by 1,159
Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family
Montgomery, R. I., Warner, M. S., Lum, B. J., & Spear, P. G. (1996) · Cell · doi:10.1016/s0092-8674(00)81363-x · Cited by 1,099
Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
Martuza, R. L., Malick, A., Markert, J. M., et al. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,058
Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D. G., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976
Research works printed but not linked: 11
- ANDREANSKY S., 1997, Cancer Res., 57, 1502
- BOVIATSIS E.J., 1994, Gene Ther., 1, 323
- DILBER M.S., 1997, Cancer Res., 57, 1523
- 10.1089/10430349850019445 · DOI
- HUARD J., 1995, Gene Ther., 2, 385
- MORGAN C., 1968, I. Entry. J. Virol., 2, 507
- MORIUCHI S., 1998, Cancer Res., 58, 5731
- OSTENSEN M.E., 1989, J. Biol. Response Mod., 8, 53
- RAJCANI J., 1998, Acta Virol., 42, 103
- ROSENBLUM M.G., 1989, Crit. Rev. Immunol., 9, 21
- RUBSAM L.Z., 1999, Cancer Res., 59, 669
Cited by
Sorted by citations
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
Ghosh, S., Brown, A. M., Jenkins, C., & Campbell, K. (2020) · Applied Biosafety · doi:10.1177/1535676019899502 · Cited by 218
de Silva, S., & J. Bowers, W. (2011) · Current Gene Therapy · doi:10.2174/156652311797415845 · Cited by 20
Metadata
- Authors
- Burton, E. A., Fink, D. J., & Glorioso, J. C.
- Affiliations
- University of Oxford (GB)
- University of Pittsburgh (US)
- Venue
- DNA and Cell Biology
- Publisher
- SAGE Publications
- Published
- 2002-12
- Volume
- 21
- Issue
- 12
- Pages
- 915-936
- ISSN
- 1044-5498 (ISSN-L)
- 1557-7430
- OpenAlex
- W2173140585
- Cited by
- 92
- References
- 245
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 6 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 2 · 2015: 3 · 2014: 2 · 2012: 1
- FWCI
- 1.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- DNA and Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- herpes simplex virus vectors, gene delivery, replication-defective vectors, immediate early genes, latent infection, sensory neurons, viral tropism, neurological disease models, glioma, peripheral neuropathy, chronic pain, neurodegeneration, viral vectors
- MeSH terms
- Animals, Defective Viruses, Genetic Vectors, Glioma, Herpes Simplex, Humans, Nervous System, Virus Replication, Genetic Therapy, Gene Expression Regulation, Viral, Drug Delivery Systems, Central Nervous System Neoplasms, Gene Transfer Techniques, Simplexvirus, Transgenes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
